Utility of modified Glasgow prognostic score for head and neck squamous cell carcinoma: Systematic review and meta‐analysis-Reference-Cited by-同舟云学术

Utility of modified Glasgow prognostic score for head and neck squamous cell carcinoma: Systematic review and meta‐analysis

Published:2023-05-10 Issue:7 Volume:45 Page:1856-1867
ISSN:1043-3074
Container-title:Head & Neck
language:en
Short-container-title:Head & Neck

Author:

Luan Chih‐Wei¹²³^ORCID,Kuo Liang‐Tseng²⁴,Wang Yun‐Ting⁵^ORCID,Liao Chun‐Ta²⁶,Kang Chung‐Jan²⁶,Lee Yi‐Chan²⁷^ORCID,Chen Kuan‐Yin⁸,Lai Chia‐Hsuan²⁹,Tsai Yuan‐Hsiung²¹⁰,Huang Ethan I.²⁵,Tsai Ming‐Shao²⁵,Hsu Cheng‐Ming²⁵^ORCID,Chang Geng‐He²⁵,Tsai Yao‐Te²⁵^ORCID

Affiliation:

1. Department of Otorhinolaryngology – Head and Neck Surgery LO‐Sheng Hospital Ministry of Health and Welfare‐Home Taoyuan Taiwan

2. College of Medicine Chang Gung University Taoyuan Taiwan

3. Lunghwa University of Science and Technology Taoyuan Taiwan

4. Division of Sports Medicine, Department of Orthopedic Surgery Chang Gung Memorial Hospital Chiayi Taiwan

5. Department of Otorhinolaryngology – Head and Neck Surgery Chang Gung Memorial Hospital Chiayi Taiwan

6. Department of Otorhinolaryngology – Head and Neck Surgery Chang Gung Memorial Hospital Taoyuan Taiwan

7. Department of Otorhinolaryngology – Head and Neck Surgery Chang Gung Memorial Hospital Keelung Taiwan

8. School of Dentistry National Yang Ming University Hsinchu Taiwan

9. Department of Radiation Oncology Chang Gung Memorial Hospital Chiayi Taiwan

10. Department of Diagnostic Radiology Chang Gung Memorial Hospital Chiayi Taiwan

Abstract

AbstractWhether the modified Glasgow prognostic score (mGPS) is useful for patients with head and neck squamous cell carcinoma (HNSCC) remains controversial. An electronic database search on EMBASE, PubMed, and the Cochrane Library from inception to 30 June 2022 was performed for study selection and data extraction. The associations between the mGPS and survival outcomes were evaluated using a random‐effects meta‐analysis and expressed as pooled hazard ratios (HRs) and 95% CIs. We included 11 studies involving a total of 2017 patients with HNSCC. A higher mGPS was associated with poorer progression‐free survival (HR = 2.39, 95% CI 1.69–3.38), overall survival (HR = 2.40, 95% CI 1.94–2.98), disease‐specific survival (HR = 2.57, 95% CI 1.71–3.88), and disease‐free survival (HR = 2.67, 95% CI 1.51–4.73, all p ≤ 0.001) in HNSCC. The mGPS can function as a valid prognostic biomarker for patients diagnosed as having HNSCC.

Funder

Chang Gung Medical Foundation

Publisher

Wiley

Subject

Otorhinolaryngology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hed.27397

Reference46 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Global Burden of Head and Neck Cancer: Economic Consequences, Health, and the Role of Surgery

3. Long‐term Survival in Head and Neck Cancer: Impact of Site, Stage, Smoking, and Human Papillomavirus Status

4. Epidemiology and Demographics of the Head and Neck Cancer Population

5. Distant metastases in head and neck cancer